UBS Initiates Coverage On Odyssey Therapeutics with Buy Rating, Announces Price Target of $27

UBS analyst Alice Nettleton has initiated coverage on Odyssey Therapeutics (NASDAQ: ODTX) with a Buy rating. The firm has set a price target of $27 for the company's stock.